During the past decade, Klinische Forschung Berlin Mitte conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Klinische Forschung Berlin Mitte" are "Dyslipidemia" (2 trials), "Hypercholesterolemia" (2 trials), "Psoriasis" (2 trials), "Dyslipidemias" (1 trials) and "Hypercholesterolemia or Combined Dyslipidemia" (1 trials). Many other conditions were trialed in "Klinische Forschung Berlin Mitte" in a lesser frequency.

Most popular intervention types in "Klinische Forschung Berlin Mitte" are "Drug" (6 trials). Other intervention types were less common.

The name of intervention was led by "Pitavastatin" (4 trials), "Mirikizumab" (2 trials), "Atorvastatin" (1 trials), "Placebo" (1 trials) and "Pravastatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Klinische Forschung Berlin Mitte" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Klinische Forschung Berlin Mitte". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Klinische Forschung Berlin Mitte, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Klinische Forschung Berlin Mitte, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".